Toxicities of Targeted Therapy and Their Management in Kidney Cancer

Di Lorenzo G., Porta C., Bellmunt J., Sternberg C., Kirkali Z., Staehler M., ...More

EUROPEAN UROLOGY, vol.59, no.4, pp.526-540, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 59 Issue: 4
  • Publication Date: 2011
  • Doi Number: 10.1016/j.eururo.2011.01.002
  • Journal Name: EUROPEAN UROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.526-540
  • Keywords: Metastatic renal cell cancer, Targeted agents, Toxicity, RENAL-CELL CARCINOMA, ANGIOGENESIS INHIBITOR BEVACIZUMAB, ENDOTHELIAL GROWTH-FACTOR, INTERFERON-ALPHA, EUROPEAN-SOCIETY, DOUBLE-BLIND, TASK-FORCE, SORAFENIB, SUNITINIB, RISK
  • Dokuz Eylül University Affiliated: Yes

Abstract

Context: The therapeutic scenario for metastatic renal cell carcinoma (mRCC) has been evolving rapidly, with sunitinib, sorafenib, bevacizumab, everolimus, pazopanib, and temsirolimus being successfully tested and approved in a short period of time. Oncologists must be familiar with the management of toxicity that these biologic agents cause, as such toxicity is different from that of conventional chemotherapeutic agents.